StockNews.com Initiates Coverage on Athersys (NASDAQ:ATHX)

Equities researchers at StockNews.com initiated coverage on shares of Athersys (NASDAQ:ATHXGet Free Report) in a note issued to investors on Wednesday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock.

Athersys Price Performance

The company has a market capitalization of $833,000.00, a price-to-earnings ratio of -0.01 and a beta of -0.90. Athersys has a 12-month low of $0.01 and a 12-month high of $1.99.

About Athersys

(Get Free Report)

Athersys, Inc, a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions.

Further Reading

Receive News & Ratings for Athersys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athersys and related companies with MarketBeat.com's FREE daily email newsletter.